PDCD1 and neoplasm: A study on a mouse tumor model showed that the efficacy of elotuzumab was significantly higher when coadministered with anti-PD-1 antibody, thus promoting tumor-infiltrating NK and CD8+ T-cell activation, as well as augmented intratumoral cytokine and chemokine release.